The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12. CooperVision’s MiSight lens is a soft, single-use and disposable contact, made to be discarded at the end of each day. […]
Alkermes has agreed to acquire Rodin Therapeutics for up to $950 million, in a deal that will expand the buyer’s CNS pipeline with first-in-class, orally-available, brain-permeable therapeutics for brain diseases driven by synaptic loss and dysfunction, or synaptopathies.
The post Alkermes to Acquire Rodin Therapeutics for Up to $950M, Expanding CNS Pipeline appeared first on GEN - Genetic Engineering and Biotechnology News. […]
Novo Nordisk is betting $225 million on Dicerna’s RNAi platform in an R&D collaboration focused on liver-related diseases and conditions, including nonalcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. It is promising another $75 million in near-term cash, as well as hundreds of millions in milestones in the heavily backloaded deal. […]
Biofourmis has been tapped by Novartis to help develop digital therapeutic programs that follow patients home after they’ve been recently diagnosed with heart failure. At the same time, Biofourmis announced plans to acquire Biovotion, makers of clinical-grade wearable biosensors. […]
Just a month ago, Alkermes was announcing it was slashing scores of jobs; now, it’s willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics. […]